This HTML5 document contains 69 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00580/identifier/pharmgkb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00580/identifier/pdb/
n11http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00580/identifier/bindingdb/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00580/identifier/pubchem-compound/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00580/identifier/pubchem-substance/
n25http://bio2rdf.org/drugbank:
n22http://linked.opendata.cz/resource/drugbank/drug/DB00580/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n21http://www.drugs.com/mtm/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00580/identifier/national-drug-code-directory/
n8http://www.rxlist.com/cgi/generic/
n24http://linked.opendata.cz/resource/drugbank/patent/
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00580/identifier/chemspider/
n5http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n4http://linked.opendata.cz/resource/atc/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00580/identifier/wikipedia/
n3http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00580
rdf:type
n5:Drug
n5:description
Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about possible increased risk of heart attack and stroke.
n5:group
withdrawn investigational
n5:halfLife
8-11 hours
n5:indication
For the treatment of osteoarthritis and dysmenorrhoea
n5:manufacturer
n11:271B4DAF-363D-11E5-9242-09173F13E4C5
owl:sameAs
n16:DB00580 n25:DB00580
dcterms:title
Valdecoxib
adms:identifier
n10:119607 n12:46506229 n13:COX n14:PA10226 n17:13063 n19:0025-1975-31 n20:106796 n22:DB00580 n23:Valdecoxib
n5:mechanismOfAction
Both COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the precursor of PGs and thromboxane. Valdecoxib selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, important for the mediation of inflammation and pain. Unlike non-selective NSAIDs, valdecoxib does not inhibit platelet aggregation.
n5:packager
n11:271B4DA9-363D-11E5-9242-09173F13E4C5 n11:271B4DAE-363D-11E5-9242-09173F13E4C5 n11:271B4DAC-363D-11E5-9242-09173F13E4C5 n11:271B4DAD-363D-11E5-9242-09173F13E4C5 n11:271B4DAA-363D-11E5-9242-09173F13E4C5 n11:271B4DAB-363D-11E5-9242-09173F13E4C5
n5:patent
n24:2212836 n24:7135489 n24:5633272
n5:routeOfElimination
Valdecoxib is eliminated predominantly via hepatic metabolism with less than 5% of the dose excreted unchanged in the urine and feces. About 70% of the dose is excreted in the urine as metabolites, and about 20% as valdecoxib N-glucuronide.
n5:toxicity
Symptoms following acute NSAID overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression and coma may occur, but are rare.
n5:volumeOfDistribution
* 86 L
n5:proteinBinding
98%
n5:synthesisReference
Eswaraiah Sajja, Anumula Reddy, Aalla Sampath, Gilla Goverdhan, "Process for preparing crystalline form A of valdecoxib." U.S. Patent US20050272787, issued December 08, 2005.
foaf:page
n8:bextra.htm n21:valdecoxib.html
n5:IUPAC-Name
n6:271B4DB4-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B4DBA-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B4DB9-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B4DB6-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B4DB7-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B4DB8-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B4DB2-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B4DCA-363D-11E5-9242-09173F13E4C5 n6:271B4DB3-363D-11E5-9242-09173F13E4C5 n6:271B4DB0-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B4DB1-363D-11E5-9242-09173F13E4C5
n3:hasATCCode
n4:M01AH03
n5:H-Bond-Acceptor-Count
n6:271B4DC0-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B4DC1-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B4DBB-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B4DBC-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B4DBE-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B4DBD-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B4DBF-363D-11E5-9242-09173F13E4C5
n5:absorption
Oral bioavailability is 83%.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
181695-72-7
n5:category
n5:clearance
* oral cl=6 L/h * 6 – 7 L/h [In patients undergoing hemodialysis] * 6 – 7 L/h [healthy elderly subjects]
n5:Bioavailability
n6:271B4DC6-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B4DC8-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B4DC9-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B4DC5-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B4DC4-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B4DC7-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B4DB5-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B4DC2-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B4DC3-363D-11E5-9242-09173F13E4C5